Overview

  • Product name

    Anti-MEK1 + MEK2 antibody [EPR16667] (HRP)
    See all MEK1 + MEK2 primary antibodies
  • Description

    Rabbit monoclonal [EPR16667] to MEK1 + MEK2 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment within Human MEK1 + MEK2 aa 1 to the C-terminus. The exact sequence is proprietary. Also SwissProt ID: P36507
    Database link: Q02750

  • Positive control

    • WB: HeLa whole cell lysate; Human fetal brain, Mouse and Rat brain tissue lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Stable for 12 months at -20°C. Store In the Dark.
  • Storage buffer

    pH: 7.40
    Preservative: 0.1% Proclin
    Constituents: PBS, 30% Glycerol, 1% BSA
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

    Monoclonal
  • Clone number

    EPR16667
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab200179 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/20000. Detects a band of approximately 44 kDa (predicted molecular weight: 43, 44 kDa).

Target

  • Function

    Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
  • Tissue specificity

    Widely expressed, with extremely low levels in brain.
  • Involvement in disease

    Cardiofaciocutaneous syndrome 3
  • Sequence similarities

    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Domain

    The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1.
  • Post-translational
    modifications

    Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (RAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Cellular localization

    Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body. Cytoplasm. Nucleus. Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis.
  • Information by UniProt
  • Database links

  • Alternative names

    • AA589381 antibody
    • CFC3 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 2 antibody
    • EC 2.7.12.2 antibody
    • ERK activator kinase 1 antibody
    • ERK activator kinase 2 antibody
    • FLJ26075 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase kinase 2 antibody
    • MAP2K1 antibody
    • MAP2K2 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPK/ERK kinase 2 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MAPKK2 antibody
    • MEK 1 antibody
    • MEK1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • Mitogen activated protein kinase kinase 2 antibody
    • Mitogen-activated protein kinase kinase 2, p45 antibody
    • MK2 antibody
    • MKK 1 antibody
    • MKK 2 antibody
    • MKK1 antibody
    • MKK2 antibody
    • MP2K1_HUMAN antibody
    • PRKMK 1 antibody
    • PRKMK 2 antibody
    • Prkmk1 antibody
    • Prkmk2 antibody
    • protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase, mitogen-activated, kinase 1 antibody
    • Protein kinase, mitogen-activated, kinase 2 antibody
    see all

Images

  • All lanes : Anti-MEK1 + MEK2 antibody [EPR16667] (HRP) (ab200179) at 1/5000 dilution

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : Fetal Brain (Human) Normal Tissue lysate
    Lane 3 : Brain (Mouse) Tissue Lysate
    Lane 4 : Brain (Rat) Tissue Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 43, 44 kDa
    Observed band size: 43 kDa
    why is the actual band size different from the predicted?



    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200179 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab200179 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab200179.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up